SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

NCT03217617 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
10
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Shenzhen Geno-Immune Medical Institute